Ablynx NV, a pioneering biopharmaceutical company headquartered in Belgium, focuses on the development of innovative therapies based on its proprietary Nanobody technology. Founded in 2001, Ablynx has made significant strides in the biotechnology sector, particularly in the fields of immunology and oncology. The company’s core offerings include a range of Nanobody-based therapeutics, which are unique due to their small size and ability to target specific proteins with high precision. This innovative approach has positioned Ablynx as a leader in the biopharmaceutical industry, with notable achievements including successful partnerships and advancements in clinical trials. With a strong presence in Europe and expanding operations globally, Ablynx continues to drive forward in the quest for transformative medical solutions.
We don't have data for Ablynx NV, but we can show you information about their parent organization instead.
View parent company